BNP Paribas reissued their outperform rating on shares of Shire PLC (LON:SHP) in a report released on Wednesday. The firm currently has a GBX 5,900 ($78.58) price objective on the biopharmaceutical company’s stock.

Several other brokerages have also commented on SHP. JPMorgan Chase & Co. restated an overweight rating and issued a GBX 6,300 ($83.91) price objective on shares of Shire PLC in a report on Tuesday, August 16th. Shore Capital restated a buy rating on shares of Shire PLC in a report on Friday, August 12th. Citigroup Inc. restated a buy rating on shares of Shire PLC in a report on Wednesday, August 3rd. Goldman Sachs Group Inc. restated a conviction-buy rating and issued a GBX 6,300 ($83.91) price objective on shares of Shire PLC in a report on Wednesday, August 3rd. Finally, Royal Bank Of Canada restated an outperform rating on shares of Shire PLC in a report on Wednesday, August 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of Buy and an average target price of GBX 5,841.33 ($77.80).

Shire PLC (LON:SHP) opened at 5099.00 on Wednesday. Shire PLC has a 1-year low of GBX 2,707.19 and a 1-year high of GBX 5,180.00. The stock’s market cap is GBX 34.82 billion. The company has a 50-day moving average price of GBX 4,943.59 and a 200 day moving average price of GBX 4,416.34.

The firm also recently disclosed a dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 8th will be given a dividend of GBX 3.51 ($0.05) per share. This represents a dividend yield of 0.07%. The ex-dividend date is Thursday, September 8th.

In other Shire PLC news, insider Bohuon,Olivier acquired 134 shares of the business’s stock in a transaction dated Thursday, June 30th. The stock was purchased at an average price of GBX 4,463 ($59.44) per share, with a total value of £5,980.42 ($7,965.40).

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.